Sartorius Stedim Biotech (LTS:0RG8) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RG8 Sartorius Stedim Biotech SA LTS:0RG8
84 GF Score
Price €188.60
GF Value €208.47
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech FFO per Share?

FFO per Share only applies to REITs.

LTS:0RG8
84GF Score
Sartorius Stedim Biotech SA LTS:0RG8
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius Stedim Biotech (LTS:0RG8) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €188.60 is trading 9.5% below its estimated GF Value™ of €208.47. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for LTS:0RG8:

  • FFO per Share:
  • GF Value™: €208.47 vs. price of €188.60 (9.5% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the LTS:0RG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for LTS:0RG8

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€188.60
Price
€208.47
GF Value